Physician profile
Debra L Fromer
NPI 1801839642
$50,277.59
in general payments reported to CMS, 2019-2025
24 companies · $4,711 in 2025
The $4,711 reported for 2025 was more than what 85% of Urogynecology and Reconstructive Pelvic Surgery (Urology) providers received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $196 · 2021: $3,813 · 2022: $20K · 2023: $15K · 2024: $5,999 · 2025: $4,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $1,240 · Travel and Lodging: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,440.83 |
| Food and Beverage | $1,240.05 |
| Travel and Lodging | $1,165.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45,980.79 | 2021-2025 | |
| Boston Scientific Corporation | $1,144.92 | 2019-2025 | General - Kidney Stone Disease, Axonics |
| Medtronic, INC. | $865.34 | 2022-2024 | Percept Pc Brainsense, Interstim |
| Zoll Medical Corporation | $660.83 | 2023 | |
| Axonics, INC. | $498.32 | 2021-2024 | Bulkamid, Axonics |
| Coloplast Corp | $346.59 | 2020-2022 | |
| Becton, Dickinson and Company | $280.00 | 2024 | |
| Shockwave Medical, INC | $124.28 | 2021 | |
| Histosonics, INC. | $65.43 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $60.93 | 2023-2025 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $35.33 | 2022-2023 | Jelmyto |
| Abbvie INC. | $28.33 | 2023 | |
| Bluewind Medical | $27.62 | 2025 | |
| Calyxo, INC. | $23.07 | 2023 | Cvac Aspiration System |
| Civco Medical Instruments | $18.23 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $17.72 | 2025 | Azmiro |
| Dentsply Ih Ab | $17.39 | 2025 | Lofric |
| Janssen Biotech, INC. | $15.51 | 2025 | Erleada |
| Tolmar, INC. | $15.38 | 2024 | |
| Medtronic USA, INC. | $14.26 | 2020 | |
| Allergan, INC. | $14.19 | 2020 | |
| Astellas Pharma US INC | $14.07 | 2022 | |
| Amniox Medical, INC. | $9.06 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Fromer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.